Agios Pharmaceuticals

Agios Pharmaceutical Inc.
Company typePublic
Nasdaq: AGIO
Russell 1000 Component
IndustryPharmaceuticals
Founded2008; 16 years ago (2008)
Headquarters
Cambridge, Massachusetts
,
United States
Key people
Brian Goff (CEO)
RevenueIncrease $118 Million(2019)[1]
Number of employees
536
Websiteagios.com
Footnotes / references
Foundation[2]

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias.[3] The company was founded in 2008 (or 2007)[4] by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.[2][5] The company tendered an initial public offering in July 2013.[6]: Table 1 

  1. ^ "Agios Reports Fourth Quarter and Full Year 2019 Financial Results – Agios Pharmaceuticals, Inc".
  2. ^ a b Cite error: The named reference burns2012 was invoked but never defined (see the help page).
  3. ^ "About Us".
  4. ^ Cite error: The named reference pollack2012 was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference 10k2013 was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference huggett2013 was invoked but never defined (see the help page).